Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback
Share
Novartis saw a treatment for a rare muscle-wasting disease fail a late-stage study, the third clinical-trial setback in a week. The medicine was the centerpiece of Novartis's $12 billion takeover of Avidity Biosciences and raises questions about the drugmaker's growth prospects. Fabienne Kinzelmann reports on Bloomberg Television.
More from Australia
Coast Entertainment maps $260M Dreamworld plan
QMines raises $5.5M for Queensland project
Yari Resources reviews 199 historical drill holes
Reserve Bank of Australia increases cash rate to 4.85%
Mount Ridley Mines extracts 96% vanadium from test
Greenvale Energy begins grant-funded airborne uranium survey